Inventor · disambiguated record
Heather Raymon
Also filed as: RAYMON HEATHER · RAYMON HEATHER K · RAYMON HEATHER KAREN
23 granted patents·16 pending applications·140 citations·filing 1998–2023
95Inventor score
Files withSIGNAL PHARM LLC28CELGENE CORP4SIGNAL PHARM INC3ARTIVA BIOTHERAPEUTICS INC2BENNETT BRYDON L1
Top patents by PatentIndex Score
39 records- 0197US9512124B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Dec 6, 2016·32 cites·60 claims
- 0296US9737541B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2016·Granted Aug 22, 2017·12 cites·52 claims
- 0392US9493466B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2012·Granted Nov 15, 2016·7 cites·5 claims
- 0489US9505764B2Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2014·Granted Nov 29, 2016·11 cites·33 claims
- 0588US7354947B2Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2005·Granted Apr 8, 2008·10 cites·4 claims
- 0685US10940152B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2020·Granted Mar 9, 2021·1 cites·27 claims
- 0785US6987184B2Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods relatedSIGNAL PHARM LLC·Filed 2002·Granted Jan 17, 2006·19 cites·4 claims
- 0884US10646493B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2019·Granted May 12, 2020·1 cites·20 claims
- 0984US2023158035A1Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2023·Application pending·0 cites
- 1083US8680076B2Methods of treatment, improvement and prevention using haloaryl substituted aminopurinesBENNETT BRYDON L·Filed 2011·Granted Mar 25, 2014·15 cites·18 claims
- 1182US9937170B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2016·Granted Apr 10, 2018·1 cites·5 claims
- 1281US9630966B2Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2014·Granted Apr 25, 2017·4 cites·6 claims
- 1377US9782427B2Methods for treating cancer using TOR kinase inhibitor combination therapySIGNAL PHARM LLC·Filed 2014·Granted Oct 10, 2017·3 cites·9 claims
- 1475US11590139B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2021·Granted Feb 28, 2023·0 cites·52 claims
- 1574US2022273650A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2021·Application pending·0 cites
- 1671US11166950B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2018·Granted Nov 9, 2021·0 cites·5 claims
- 1771US2023338370A1Treatment of Cancer with TOR Kinase InhibitorsSIGNAL PHARM LLC·Filed 2022·Application pending·0 cites
- 1864US6835567B1PNS cell lines and methods of use thereforSIGNAL PHARM INC·Filed 1998·Granted Dec 28, 2004·15 cites·31 claims
- 1960US2021371522A1Cd47 antibodies and methods of use thereofCELGENE CORP·Filed 2021·Application pending·0 cites
- 2060US2005124007A1Human mesencephalon cell lines and methods of use thereforSIGNAL PHARM INC·Filed 2004·Application pending·0 cites
- 2160US2005095701A1PNS cell lines and methods of use thereforSIGNAL PHARM INC·Filed 2004·Application pending·0 cites
- 2258US9937169B2Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapySIGNAL PHARM LLC·Filed 2014·Granted Apr 10, 2018·0 cites·4 claims
- 2358US2024424099A1Treatment of cancer with nk cells and multispecific engagersARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2457US12084499B2SIRP-α binding proteins and methods of use thereofCELGENE CORP·Filed 2023·Granted Sep 10, 2024·0 cites·31 claims
- 2556US10391092B2Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapySIGNAL PHARM LLC·Filed 2018·Granted Aug 27, 2019·0 cites·9 claims
- 2655US6913925B1Human mesencephalon cell lines and methods of use thereforSIGNAL PHARM LLC·Filed 1998·Granted Jul 5, 2005·9 cites·17 claims
- 2753US10183019B2Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2017·Granted Jan 22, 2019·0 cites·5 claims
- 2853US2014314673A1Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2014·Application pending·0 cites
- 2953US2025073264A1Chimeric antigen receptor comprising an anti-her2 antibody or antigen-binding fragment thereof and natural killer cells comprising the sameARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3052US9980963B2Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2016·Granted May 29, 2018·0 cites·11 claims
- 3152US2009270418A1Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewithSLOSS MARIANNE·Filed 2009·Application pending·0 cites
- 3252US2004092562A1Methods for treating inflammatory conditions or inhibiting JNKSIGNAL PHARM LLC·Filed 2003·Application pending·0 cites
- 3350US2013245027A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 3447US2020255515A1Cd47 antibodies and methods of use thereofCELGENE CORP·Filed 2017·Application pending·0 cites
- 3546US11591390B2SIRP-α binding proteins and methods of use thereofCELGENE CORP·Filed 2019·Granted Feb 28, 2023·0 cites·24 claims
- 3643US2014113904A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 3742US2013245026A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 3842US2013245028A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 3938US10576085B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2017·Granted Mar 3, 2020·0 cites·22 claims
Join the waitlist — get patent alerts
Get an alert when Heather Raymon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →